Press Releases April 21, 2026 09:01 AM

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

Stereotaxis schedules Q1 2026 earnings release and conference call for May 12, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
STXS

Stereotaxis, a leader in surgical robotics for minimally invasive endovascular intervention, announced its intention to release first quarter 2026 financial results on May 12, 2026. The company will host a conference call to discuss the results and corporate updates.

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
STXS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Stereotaxis is a pioneer in surgical robotics, focused on minimally invasive endovascular interventions.
  • The company will report Q1 2026 financial results following the U.S. market close on May 12, 2026.
  • A webcast and conference call will be held to discuss the financial performance and corporate developments.

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

What: Stereotaxis first quarter 2026 financial results conference call   When: Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT)   Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 6082771.   Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.   Call Replay: A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.   

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer                        
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
[email protected]


Risks

  • Financial results may fall short of market expectations, affecting investor sentiment in the healthcare robotics sector.
  • Potential operational or market challenges could affect Stereotaxis' growth in the medical technology industry.
  • Uncertainty about adoption rates of robotic surgical systems and reimbursement policies impacting revenue growth.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026